Aktienanalyse zu Tyra Biosciences Inc (TYRA)TYRATyra Biosciences Inc

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help it design and predict which candidates may demonstrate highest potency, selectivity and tolerability in clinic. Its expertise in FGFR biology has created a pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for LG-UTUC, IR NMIBC and ACH. It is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in SURF431 study (advanced hepatocellular carcinoma), and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in SURF201 study (metastatic intrahepatic cholangiocarcinoma). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Tyra Biosciences is currently priced at $24.94, with a recent RSI of 30.448 indicating oversold conditions. However, the company has reported significant net losses, with Q2 2026 EPS at -0.69, missing expectations, and a forward P/E ratio of 0, suggesting uncertainty in future earnings. The analyst price targets range from $39 to $56, indicating potential upside, but the recent insider selling activity has increased by 100.98%, which raises concerns about confidence in the stock. Given these factors, it may be prudent to hold off on buying until there are clearer signs of recovery or stability in earnings.